Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
With five histone deacetylase (HDAC) inhibitors approved for cancer treatment, proteolysis-targeting chimeras (PROTACs) for degradation of HDAC are emerging as an alternative strategy for HDAC-targeted therapeutic intervention. Herein, three bestatin-based hydroxamic acids (
,
and
) were designed, synthesized and biologically evaluated to...
Alternative Titles
Full title
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_037ce3714cb44682aca94338e87fff47
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_037ce3714cb44682aca94338e87fff47
Other Identifiers
ISSN
1420-3049
E-ISSN
1420-3049
DOI
10.3390/molecules25214991
